Myriad Genetics (FRA:MYD) Growth Rank: 1 (As of Sep. 16, 2026) — 80% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MYD Myriad Genetics Inc FRA:MYD
42 GF Score
Price €3.23
GF Value €9.49
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Myriad Genetics Growth Rank?

Myriad Genetics FRA:MYD +11.38% 42 Growth Rank is 1 as of Sep. 16, 2026, which is 80% below its 10-year median of 5.00. GuruFocus rates FRA:MYD with a GF Score™ of 42/100 and a GF Value™ of €9.49 (Possible Value Trap). The stock has 3 warning signs investors should review.

Myriad Genetics has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Myriad Genetics Growth Rank Related Terms

FRA:MYD vs BDSX, XGN, IMDX: Growth Rank Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myriad Genetics Growth Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Growth Rank falls into.


FRA:MYD
42GF Score
Myriad Genetics Inc FRA:MYD
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
Myriad Genetics (FRA:MYD) has a Growth Rank of 1 as of Sep. 16, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Myriad Genetics and its competitors. This is 80% below median its historical median of 5.00. Over the past decade, Myriad Genetics' Growth Rank has ranged from 2.00 to 10.00.
Is Myriad Genetics' Growth Rank too high?
Myriad Genetics' current Growth Rank of 1 is 80% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Myriad Genetics has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Growth Rank compare to BDSX and XGN?
Myriad Genetics' Growth Rank of 1 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Myriad Genetics' own Growth Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Diagnostics & Research company?
A good Growth Rank depends on the Medical Diagnostics & Research industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Growth Rank is 1, which is 80% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (FRA:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €9.49, compared to a current price of €3.23 — trading 66% below its estimated fair value. The current Growth Rank is 1, which is 80% below median its 10-year median of 5.00. Myriad Genetics' overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Myriad Genetics (FRA:MYD), the current Growth Rank is 1 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (FRA:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €3.23 is trading 66% below its estimated GF Value™ of €9.49. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for FRA:MYD:

  • Growth Rank: 1 (80% below median its 10-year median of 5.00)
  • GF Value™: €9.49 vs. price of €3.23 (66% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UK
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
42GF Score

Get the complete analysis for FRA:MYD

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.23
Price
€9.49
GF Value